The Hibiscus Study is evaluating the safety and effectiveness of an investigational medication on improving anemia and reducing the number of annual sickle cell crises in people 12 to 65 years of age with sickle cell disease (SCD).
Eligible participants must:
There are additional eligibility requirements, which the investigator will explain to you.
Participation in this study will last up to 113 weeks, which is just over 2 years, and will require up to 25 visits throughout the course of the study. This includes:
Throughout the study, the investigator may perform a number of tests and procedures, including but not limited to:
Those who qualify and enroll in this study will receive the investigational medication (or placebo), as well as all tests and procedures that are done just for this study, at no cost.
Reimbursement may be available for the following: